# A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

> **NCT01035216** · PHASE1 · TERMINATED · sponsor: **SBI Biotech Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** GNKG168

## Key facts

- **NCT ID:** NCT01035216
- **Lead sponsor:** SBI Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** This study has been terminated.
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035216, "A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01035216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*